InnoCare Pharma (9969) investor relations material

Executive summary

• Achieved strong financial performance in H1 2026, with revenue of RMB 1,137.1 million, up 55.5% year-over-year, and net profit of RMB 239.7 million, reversing a prior-year loss, driven by robust drug sales and milestone collaboration income.

• Maintained a robust cash position of RMB 8.4 billion as of June 30, 2026, supporting ongoing R&D, global expansion, and commercialization.

• Expanded commercial portfolio with orelabrutinib, tafasitamab, and zurletrectinib, strengthening presence in hematologic oncology, solid tumors, and autoimmune diseases.

• Advanced a diversified late-stage pipeline in oncology and autoimmune diseases, with multiple regulatory and clinical milestones achieved.

• Key milestones included NDA approvals and submissions, new product launches, and strategic collaborations.

Financial highlights

• Total revenue reached RMB 1,137.1 million, a 55.5% year-over-year increase; drug sales were RMB 918.1 million, up 43.2% year-over-year.

• Net profit was RMB 239.7 million, compared to a loss of RMB 35.6 million in H1 2025; diluted EPS was RMB 0.14.

• Gross profit increased 55.5% to RMB 1,018.1 million, with gross margin stable at 89.5%.

• R&D expenses grew 10.5% year-over-year to RMB 497 million; operating expenses increased 11.4% to RMB 878.4 million.

• Cash and related balances stood at RMB 8.4 billion as of June 30, 2026.

Outlook and guidance

• Confident in exceeding 35% full-year drug sales growth for 2026 and maintaining profitability, with EPS projected to be higher in H2.

• Multiple clinical and regulatory milestones anticipated across all portfolios, with continued focus on commercialization and global development.